{
    "nctId": "NCT02955394",
    "briefTitle": "Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer",
    "officialTitle": "Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 61,
    "primaryOutcomeMeasure": "Number of Patients With a PEPI Score Equal to Zero at Post Treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* ER+ Her2- breast cancer\n* Stage at least T2 or greater\n* Planned to get local surgery\n* Postmenopausal, or if pre- or peri- menopausal, then will need to have concurrent ovarian suppression.\n* At least 18 years of age\n* Not on anticoagulants\n* PS 0-2\n* Able to swallow study drug and comply with study requirements\n* ANC \\>1000/uL, platelets \\>75,000/uL at screening visit\n* Total bilirubin \\< 1.5 times upper limit of normal (ULN) at the screening visit unless an alternate nonmalignant etiology exists (eg, Gilbert's disease)\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\< 3 times ULN or \\< 5 times ULN if patient has documented liver metastases\n* Creatinine \\< 1.5 times ULN\n* INR \\< 1.5 times ULN, or if on warfarin, can safely transition off for biopsy\n* Willing to donate blood for research at 4 time points\n* Willing to undergo core biopsies for research at study entry and at \\~4 weeks.\n* Willing to donate tissue to research from the surgical specimen\n* Written informed consent obtained prior to biopsies and blood samples\n\nExclusion Criteria:\n\n* Current or previously treated brain or leptomeningeal metastases\n* History of seizures\n* Prior treatment with an anti-androgen (abiraterone, ARN-509, bicalutamide, enzalutamide, ODM-201, TAK-448, TAK-683, TAK-700, VT-464).\n* Systemic estrogens or androgens within 14 days before initiating therapy. Vaginal estrogens are allowed if necessary for patient comfort.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}